EFG Capital International’s Alnylam Pharmaceuticals ALNY Stock Holding History

EFG Capital International’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$2.99M	Buy	+15,735	New	+$3.12M	0.69%	45

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

EFG Capital International's ALNY Position: Q2 2023 in Review

EFG Capital International opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2023: 15,735 shares worth $2.99M. The stake represents 0.69% of the portfolio and ranks #45 among its holdings.

476 funds tracked by Wall St. Rank hold ALNY as of Q2 2023.

EFG Capital International held 15,735 shares of Alnylam Pharmaceuticals worth $2.99M as of Q2 2023.
Alnylam Pharmaceuticals was a new EFG Capital International position in Q2 2023.
Alnylam Pharmaceuticals made up 0.69% of EFG Capital International's portfolio in Q2 2023, its #45 holding.
476 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2023.

Based on EFG Capital International's 13F filing for Q2 2023, filed 2 Aug 2023.